Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Cited by (1,049)

Items 101–200 of 1,049

1. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
   Leticia De Mattos‐Arruda, Regina Mayor, Charlotte K.Y. Ng, Britta Weigelt, Francisco Martínez Ricarte, Davis Yuri Torrejon, Mafalda Oliveira, Alexandra Arias, C. Raventós, Jiabin Tang et al. · 2015 · Nature Communications
2. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
   Lichun Ma, Maria Olga Hernandez, Yongmei Zhao, Monika Mehta, Bao Quoc Tran, Michael C. Kelly, Zachary Rae, Jonathan Matthew Hernandez, Jeremy L. Davis, Sean P. Martin et al. · 2019 · Cancer Cell
3. The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
   Caleb Davis, Christopher J. Ricketts, Min Wang, Lixing Yang, Andrew D. Cherniack, Hui Shen, Christian Buhay, Hyo-Jin Kang, Sang Cheol Kim, Catherine C. Fahey et al. · 2014 · Cancer Cell
4. Targeting the translation machinery in cancer
   Bhat, Mamatha, Robichaud, Nathaniel, Hulea, Laura, Sonenberg, Nahum, Pelletier, Jerry, Topisirovic, Ivan · 2015 · Nature Reviews Drug Discovery
5. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
   Francesco Favero, T. Joshi, Andrea Marion Marquard, Nicolai J. Birkbak, Marcin Krzystanek, Q. Li, Zoltán Szállási, Aron Charles Eklund · 2014 · Annals of Oncology
6. Mutational landscape and clonal architecture in grade II and III gliomas
   Suzuki, Hiromichi, Aoki, Kosuke, Chiba, Kenichi, Sato, Yusuke, Shiozawa, Yusuke, Shiraishi, Yuichi, Shimamura, Teppei, Niida, Atsushi, Motomura, Kazuya, Ohka, Fumiharu et al. · 2015 · Nature Genetics
7. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
   Samra Turajlic, Hang Xu, Kevin Litchfield, Andrew Rowan, Tim Chambers, Jose Ignacio Lopez, David L. Nicol, Tim O’Brien, James Larkin, Stuart D. Horswell et al. · 2018 · Cell
8. Tumour evolution in hepatocellular carcinoma
   Amanda J. Craig, Johann von Felden, Teresa García‐Lezana, Samantha Sarcognato, Augusto Villanueva · 2019 · Nature Reviews Gastroenterology & Hepatology
9. Subclonal diversification of primary breast cancer revealed by multiregion sequencing
   Lucy R. Yates, Moritz Gerstung, Stian Knappskog, Christine Desmedt, Gunes Gundem, Peter Van Loo, Turid Aas, Ludmil B. Alexandrov, Denis Larsimont, Helen Davies et al. · 2015 · Nature Medicine
10. Intra-tumor heterogeneity from a cancer stem cell perspective
    Pramudita R. Prasetyanti, Jan Paul Medema · 2017 · Molecular Cancer
11. PD-L1 expression in human cancers and its association with clinical outcomes
    Yu, Jinming, Wang, Xin, Teng, Feifei, Kong, Li · 2016 · OncoTargets and Therapy
12. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
    Shang‐Gin Wu, Jin‐Yuan Shih · 2018 · Molecular Cancer
13. VHL, the story of a tumour suppressor gene
    Lucy Gossage, Tim G Eisen, Eamonn Richard Maher · 2014 · Nature reviews. Cancer
14. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
    Noemi Andor, Trevor A. Graham, Marnix Jansen, Li Charlie Xia, Athena Aktipis, Claudia Katharina Petritsch, Hanlee P. Ji, Carlo C. Maley · 2015 · Nature Medicine
15. Circulating Tumor DNA as a Liquid Biopsy for Cancer
    Ellen Heitzer, Peter Ulz, Jochen B. Geigl · 2014 · Clinical Chemistry
16. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers
    Fang, Jun, Islam, Waliul, Maeda, Hiroshi · 2020 · Advanced Drug Delivery Reviews
17. Review of precision cancer medicine: Evolution of the treatment paradigm
    Apostolia Maria Tsimberidou, Elena Fountzilas, Mina Nikanjam, Razelle Kurzrock · 2020 · Cancer Treatment Reviews
18. Tumor metastasis: moving new biological insights into the clinic
    Liling Wan, Klaus Pantel, Yibin Kang · 2013 · Nature Medicine
19. Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
    Antonija Kreso, Catherine Adell O'Brien, Peter van Galen, Olga I. Gan, Faiyaz Notta, Andrew M K Brown, Karen Ng, Jing Ma, Erno Wienholds, Cyrille F. Dunant et al. · 2012 · Science
20. Immunogenicity of somatic mutations in human gastrointestinal cancers
    Tran, Eric, Ahmadzadeh, Mojgan, Lu, Yong-Chen, Gros, Alena, Turcotte, Simon, Robbins, Paul F., Gartner, Jared J., Zheng, Zhili, Li, Yong F., Ray, Satyajit et al. · 2015 · Science
21. Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
    Lawrence J. Jennings, Maria E. Arcila, Christopher L. Corless, Suzanne Kamel‐Reid, Ira M. Lubin, John D. Pfeifer, Robyn Temple‐Smolkin, Karl V. Voelkerding, Marina N. Nikiforova · 2017 · Journal of Molecular Diagnostics
22. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
    Akash Kumar, Ilsa M. Coleman, Colm M. Morrissey, Xiaotun Zhang, Lawrence D. True, Roman Gulati, Ruth Etzioni, Hamid Bolouri, Bruce Montgomery, Thomas A. White et al. · 2016 · Nature Medicine
23. Robust mapping of spatiotemporal trajectories and cell–cell interactions in healthy and diseased tissues
    Duy Pham, Xiao Tan, Brad Balderson, Jun Xu, Laura F. Grice, Sohye Yoon, Emily F. Willis, Minh Tran, Pui Yeng Lam, Arti M. Raghubar et al. · 2023 · Nature Communications
24. Nanomedicine therapeutic approaches to overcome cancer drug resistance
    Markman, Janet L., Rekechenetskiy, Arthur, Holler, Eggehard, Ljubimova, Julia Y. · 2013 · Advanced Drug Delivery Reviews
25. miR-34 – a microRNA replacement therapy is headed to the clinic
    Andreas G. Bader · 2012 · Frontiers in Genetics
26. Genomic characterization of metastatic breast cancers
    François Bertucci, Charlotte K.Y. Ng, Anne Patsouris, Nathalie M Droin, Salvatore Piscuoglio, Nadine Carbuccia, Jean‐Charles Soria, Alicia Tran Dien, Yahia Adnani, Maud T Kamal et al. · 2019 · Nature
27. Targeting renal cell carcinoma with a HIF-2 antagonist
    Chen, Wenfang, Hill, Haley, Christie, Alana, Kim, Min Soo, Holloman, Eboni, Pavia-Jimenez, Andrea, Homayoun, Farrah, Ma, Yuanqing, Patel, Nirav, Yell, Paul et al. · 2016 · Nature
28. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
    Jason Keith Sicklick, Shumei Kato, Ryosuke Okamura, Maria Clemence Schwaederle, Michael E. Hahn, Casey B. Williams, Pradip K. De, Amy K. Krie, David Eric Piccioni, Vincent A. Miller et al. · 2019 · Nature Medicine
29. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
    David Tomoaki Miyamoto, Yu Zheng, Ben S. Wittner, Richard J. Lee, Huili Zhu, Katherine T. Broderick, Rushil N. Desai, Douglas B. Fox, Brian W. Brannigan, Julie Trautwein et al. · 2015 · Science
30. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA
    Lanman, Richard B., Mortimer, Stefanie A., Zill, Oliver A., Sebisanovic, Dragan, Lopez, Rene, Blau, Sibel, Collisson, Eric A., Divers, Stephen G., Hoon, Dave S. B., Kopetz, E. Scott et al. · 2015 · PLoS ONE
31. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
    Westover, D., Zugazagoitia, J., Cho, B.C., Lovly, C.M., Paz-Ares, L. · 2018 · Annals of Oncology
32. Cancer stem cell definitions and terminology: the devil is in the details
    Peter Valent, Dominique A. Bonnet, Ruggero D. Maria, Tsvee Lapidot, Mhairi Copland, Junia V. Melo, Christine Chomienne, Fumihiko Ishikawa, Jan Jacob Schuringa, Giorgio Stassi et al. · 2012 · Nature reviews. Cancer
33. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
    Ashley Maynard, Caroline Elizabeth McCoach, Julia K. Rotow, Lincoln Harris, Franziska Haderk, Daniel Lucas Kerr, Elizabeth A. Yu, Erin Lynn Schenk, Weilun Tan, Alexander Zee et al. · 2020 · Cell
34. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
    McGranahan, Nicholas, Favero, Francesco, de Bruin, Elza C., Birkbak, Nicolai Juul, Szallasi, Zoltan, Swanton, Charles · 2015 · Science Translational Medicine
35. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
    Robert J. Gillies, Daniel Verduzco, Robert A. Gatenby · 2012 · Nature reviews. Cancer
36. Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome
    O'Connor, James P.B., Rose, Chris J., Waterton, John C., Carano, Richard A.D., Parker, Geoff J.M., Jackson, Alan · 2015 · Clinical Cancer Research
37. The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review
    Aerts, Hugo J. W. L. · 2016 · JAMA Oncology
38. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
    Yun Zhang, Robert A. Weinberg · 2018 · Frontiers of Medicine
39. Renal cell carcinoma
    Eric Jonasch, Jianjun Gao, W. Kimryn Rathmell · 2014 · BMJ
40. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
    Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David Matthew Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich et al. · 2016 · Nature Communications
41. Evolution of the cancer genome
    Lucy R. Yates, Peter J. Campbell · 2012 · Nature Reviews Genetics
42. Classification of endometrial carcinoma: more than two types
    Rajmohan Murali, Robert A. Soslow, Britta Weigelt · 2014 · The Lancet Oncology
43. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
    Eric W. Jonasch, Cheryl Lyn Walker, W. Kimryn Rathmell · 2020 · Nature Reviews Nephrology
44. Evolving synergistic combinations of targeted immunotherapies to combat cancer
    Ignacio Melero, David M. Berman, Maria Angela Aznar, Alan J. Korman, José Luis Perez‐Gracia, John B.A.G. Haanen · 2015 · Nature reviews. Cancer
45. Age-related remodelling of oesophageal epithelia by mutated cancer drivers
    Yokoyama, Akira, Kakiuchi, Nobuyuki, Yoshizato, Tetsuichi, Nannya, Yasuhito, Suzuki, Hiromichi, Takeuchi, Yasuhide, Shiozawa, Yusuke, Sato, Yusuke, Aoki, Kosuke, Kim, Soo Ki et al. · 2019 · Nature
46. Identification of neutral tumor evolution across cancer types
    Marc J. Williams, Benjamin Werner, Chris P. Barnes, Trevor A. Graham, Andrea Sottoriva · 2016 · Nature Genetics
47. To differentiate or not — routes towards metastasis
    Thomas Brabletz · 2012 · Nature reviews. Cancer
48. Molecular analysis of circulating tumour cells—biology and biomarkers
    Matthew Krebs, Robert Lewin Metcalf, Louise Carter, Gerard Brady, Fiona Helen Blackhall, Caroline Dive · 2014 · Nature Reviews Clinical Oncology
49. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
    William Marston Linehan, Christopher J. Ricketts · 2019 · Nature Reviews Urology
50. Advances in targeted therapies for hepatocellular carcinoma in the genomic era
    Josep Maria Llovet, Augusto Villanueva, Anja Lachenmayer, Richard S. Finn · 2015 · Nature Reviews Clinical Oncology
51. Advances and Applications of Single-Cell Sequencing Technologies
    Yong Wang, Nicholas E. Navin · 2015 · Molecular Cell
52. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
    Kevin Bi, Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu, Grace Grimaldi, David A. Braun, Michael S. Cuoco, Angie Mayorga et al. · 2021 · Cancer Cell
53. Tumour heterogeneity and metastasis at single-cell resolution
    Lawson, Devon A., Kessenbrock, Kai, Davis, Ryan T., Pervolarakis, Nicholas, Werb, Zena · 2018 · Nature Cell Biology
54. The challenge of drug resistance in cancer treatment: a current overview
    Michail Nikolaou, Athanasia Pavlopoulou, Alexandros G. Georgakilas, Efthymios Kyrodimos · 2018 · Clinical & Experimental Metastasis
55. The Clinical Relevance of Cancer Cell Lines
    J.-P. Gillet, Sudhir Varma, Michael M. Gottesman · 2013 · JNCI Journal of the National Cancer Institute
56. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
    Peter D. Eirew, Adi Steif, Jaswinder S. Khattra, Gavin Ha, Damian Yap, Hossein Farahani, Karen A. Gelmon, Stephen Chia, Colin Mar, Adrian Wan et al. · 2014 · Nature
57. Origins of Metastatic Traits
    Vanharanta, Sakari, Massagué, Joan · 2013 · Cancer Cell
58. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity
    Andriy Marusyk, Doris P. Tabassum, Philipp M. Altrock, Vanessa Almendro, Franziska Michor, Kornélia Polyák · 2014 · Nature
59. The urgent need to recover MHC class I in cancers for effective immunotherapy
    Garrido, Federico, Aptsiauri, Natalia, Doorduijn, Elien M, Garcia Lora, Angel M, van Hall, Thorbald · 2016 · Current Opinion in Immunology
60. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
    Scott D. Brown, Robin M. Warren, Ewan A. Gibb, Spencer D. Martin, John Joseph Spinelli, Brad H. Nelson, Robert A. Holt · 2014 · Genome Research
61. The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα
    Feng Li, Guogen Mao, Dan Tong, Jian Huang, Liya Gu, Wei Yang, Guo‐Min Li · 2013 · Cell
62. Cancer Stem Cells: The Architects of the Tumor Ecosystem
    Briana C. Prager, Qi Xie, Shideng Bao, Jeremy N. Rich · 2019 · Cell stem cell
63. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
    Juric, Dejan, Castel, Pau, Griffith, Malachi, Griffith, Obi L., Won, Helen H., Ellis, Haley, Ebbesen, Saya H., Ainscough, Benjamin J., Ramu, Avinash, Iyer, Gopa et al. · 2015 · Nature
64. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
    Marius Ilié, Élodie Long-Mira, Coraline Bence, Catherine Butori, Sandra Lassalle, Linda Bouhlel, Laetitia Fazzalari, Katia Zahaf, Salomé Lalvée, Kevin Washetine et al. · 2015 · Annals of Oncology
65. Mechanisms Governing Metastatic Dormancy and Reactivation
    Giancotti, Filippo G. · 2013 · Cell
66. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
    Ramirez, Michael, Rajaram, Satwik, Steininger, Robert J., Osipchuk, Daria, Roth, Maike A., Morinishi, Leanna S., Evans, Louise, Ji, Weiyue, Hsu, Chien-Hsiang, Thurley, Kevin et al. · 2016 · Nature Communications
67. Collagen as a double-edged sword in tumor progression
    Fang, Min, Yuan, Jingping, Peng, Chunwei, Li, Yan · 2014 · Tumor Biology
68. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
    Dentro, Stefan C., Leshchiner, Ignaty, Haase, Kerstin, Tarabichi, Maxime, Wintersinger, Jeff, Deshwar, Amit G., Yu, Kaixian, Rubanova, Yulia, Macintyre, Geoff, Demeulemeester, Jonas et al. · 2021 · Cell
69. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
    Jordi Ahnert Rodon, Jean‐Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Maria Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña et al. · 2019 · Nature Medicine
70. Metabolic reprogramming in clear cell renal cell carcinoma
    Hiromi Inoue Wettersten, Omran Abu Aboud, Primo N. Lara, Robert H. Weiss · 2017 · Nature Reviews Nephrology
71. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Ray-Coquard, Isabelle, Blay, Jean-Yves, Italiano, Antoine, Le Cesne, Axel, Penel, Nicolas, Zhi, Jianguo, Heil, Florian, Rueger, Ruediger, Graves, Bradford, Ding, Meichun et al. · 2012 · The Lancet Oncology
72. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    Kathleen Margaret Mahoney, Gordon James Freeman, David F. McDermott · 2015 · Clinical Therapeutics
73. Clinical management of breast cancer heterogeneity
    Dimitrios Zardavas, Alexandre Irrthum, Charles Swanton, Martine J Piccart · 2015 · Nature Reviews Clinical Oncology
74. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity
    Emelie Berglund, Jonas Maaskola, Niklas Schultz, Stefanie Friedrich, Maja Marklund, Joseph Bergenstråhle, Firas Tarish, Anna Tanoglidi, Sanja Vicković, Ludvig Larsson et al. · 2018 · Nature Communications
75. Biomarker development in the precision medicine era: lung cancer as a case study
    Ashley J. Vargas, Curtis C. Harris · 2016 · Nature reviews. Cancer
76. Cancer stem cells: advances in knowledge and implications for cancer therapy
    Xianjing Chu, Wentao Tian, Jiaoyang Ning, Gang Xiao, Yunqi Zhou, Ziqi Wang, Zhuofan Zhai, Guilong Tanzhu, Jie Yang, Rongrong Zhou · 2024 · Signal Transduction and Targeted Therapy
77. Intra-tumour diversification in colorectal cancer at the single-cell level
    Sophie F. Roerink, Nobuo Sasaki, Henry Lee-Six, Matthew D. Young, Ludmil B. Alexandrov, Sam Behjati, Thomas J. Mitchell, Sebastian Großmann, Howard W. Lightfoot, David A. Egan et al. · 2018 · Nature
78. Translational Implications of Tumor Heterogeneity
    Mariam Jamal‐Hanjani, Sergio A. Quezada, James Larkin, Charles Swanton · 2015 · Clinical Cancer Research
79. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
    Eliezer M. Van Allen, Nikhil Wagle, Petar Stojanov, Danielle Perrin, Kristian Cibulskis, Sara Marlow, Judit Jané‐Valbuena, Dennis C. Friedrich, Gregory V. Kryukov, Scott L. Carter et al. · 2014 · Nature Medicine
80. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
    Gerald Steven Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas James DeMarini, Peng Gang Sun, Christopher H. Moy, Stephen A. Szabo, Lori Roadcap et al. · 2012 · The Lancet Oncology
81. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
    Laura Keller, Klaus Pantel · 2019 · Nature reviews. Cancer
82. The biology of circulating tumor cells
    Klaus Pantel, Michael R. Speicher · 2015 · Oncogene
83. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations
    Jesse J. Salk, Michael W. Schmitt, Lawrence A. Loeb · 2018 · Nature Reviews Genetics
84. Tumor Immunology and Tumor Evolution: Intertwined Histories
    Jérôme Galon, Daniela Bruni · 2020 · Immunity
85. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
    Apostolia Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald Steven Falchook, Siqing Fu, Sarina Anne Piha-Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra et al. · 2012 · Clinical Cancer Research
86. Fructose-1,6-bisphosphatase opposes renal carcinoma progression
    Li, Bo, Qiu, Bo, Lee, David S. M., Walton, Zandra E., Ochocki, Joshua D., Mathew, Lijoy K., Mancuso, Anthony, Gade, Terence P. F., Keith, Brian, Nissim, Itzhak et al. · 2014 · Nature
87. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer
    Jens G. Lohr, Viktor A. Adalsteinsson, Kristian Cibulskis, Atish Dipankar Choudhury, Mara W. Rosenberg, Peter Cruz‐Gordillo, Joshua M. Francis, Cheng-Zhong Zhang, Alex K. Shalek, Rahul Satija et al. · 2014 · Nature Biotechnology
88. Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
    Misale, Sandra, Di Nicolantonio, Federica, Sartore-Bianchi, Andrea, Siena, Salvatore, Bardelli, Alberto · 2014 · Cancer Discovery
89. Mitochondrial DNA copy number variation across human cancers
    Ed Reznik, Martin L. Miller, Yasin Şenbabaoğlu, Nadeem Riaz, Judy Sarungbam, Satish K. Tickoo, Hikmat A Al‐Ahmadie, William Lee, Venkatraman Seshan, A. Ari Hakimi et al. · 2016 · eLife
90. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
    Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia Mucci LoRusso, Jean-­Marc Ferrero, Tanja Badovinac-Črnjević, Silke Hoersch, Melanie C. Smitt, Hans P. M. W. Wildiers · 2017 · The Lancet Oncology
91. The multi-factorial nature of clinical multidrug resistance in cancer
    Yehuda G. Assaraf, Anamaria Brozović, Ana Cristina Gonçalves, Dana Jurkovičová, Aija Linē, Miguel Machuqueiro, Simona Saponara, Ana Bela Sarmento‐Ribeiro, Cristina P. R. Xavier, M. Helena Vasconcelos · 2019 · Drug Resistance Updates
92. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
    Woodhouse, Ryan, Li, Meijuan, Hughes, Jason, Delfosse, David, Skoletsky, Joel, Ma, Pei, Meng, Wei, Dewal, Ninad, Milbury, Coren, Clark, Travis et al. · 2020 · PLOS ONE
93. Antibody-drug conjugates—an emerging class of cancer treatment
    Nikolaos Diamantis, Udai Banerji · 2016 · British Journal of Cancer
94. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
    Mihaela Angelova, Pornpimol Charoentong, Hubert Hackl, Maria L Fischer, René Snajder, Anne Krogsdam, Maximilian J. Waldner, Gabriela Bindea, Bernhard Mlecnik, Jérôme Galon et al. · 2015 · Genome biology
95. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation
    Maura Costello, Trevor J. Pugh, Tim J. Fennell, Chip Stewart, Lee Lichtenstein, James C. Meldrim, Jennifer Fostel, Dennis C. Friedrich, Danielle Perrin, Danielle Ashley Dionne et al. · 2013 · Nucleic Acids Research
96. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
    Peter B. Makhov, Shreyas Subhash Joshi, Pooja Ghatalia, Alexander Kutikov, Robert G. Uzzo, Vladimir M. Kolenko · 2018 · Molecular Cancer Therapeutics
97. Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
    Tianhong Li, Hsing‐Jien Kung, Philip C. Mack, David R. Gandara · 2013 · Journal of Clinical Oncology
98. Glioblastoma: From Molecular Pathology to Targeted Treatment
    Timothy Francis Cloughesy, Webster K. Cavenee, Paul S. Mischel · 2011 · Annual Review of Pathology Mechanisms of Disease
99. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
    Parikh, Aparna R., Leshchiner, Ignaty, Elagina, Liudmila, Goyal, Lipika, Levovitz, Chaya, Siravegna, Giulia, Livitz, Dimitri, Rhrissorrakrai, Kahn, Martin, Elizabeth E., Van Seventer, Emily E. et al. · 2019 · Nature Medicine
100. Multifunctional Tumor pH-Sensitive Self-Assembled Nanoparticles for Bimodal Imaging and Treatment of Resistant Heterogeneous Tumors
     Daishun Ling, Wooram Park, Sin‐jung Park, Yang Lü, Kyoung Sub Kim, Michael Hackett, Byung Hyo Kim, Hyeona Yim, Yong Sun Jeon, Kun Na et al. · 2014 · Journal of the American Chemical Society